Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Gastrointestinal aluminium (A1) absorption has been proved but its mechanism is still unknown. This study investigates the pattern of A1 absorption in patients with different degrees of iron stores. We studied 29 haemodialysis patients forming three groups according to their serum ferritin values. Over seven days all patients received the same dose of aluminium hydroxide after which patients with 'low-normal' and normal serum ferritin increased their serum A1 proportionally with the increased aluminium hydroxide intake. By contrast patients with high serum ferritin did not show any change in their serum A1 values. Our results therefore suggest that a 'common pathway' of metal absorption could be implicated in A1 absorption. Serum ferritin might be a valuable predictor of different behaviour.
Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985
PMID:Gastrointestinal aluminium absorption: is it modulated by the iron-absorptive mechanism? 399 22

In six anuric haemodialysed patients, aluminium and iron mass transfer were determined 48 hours after 40 and 80mg/kg body weight desferrioxamine intravenous infusion. All patients were aluminium overloaded (mean +/- SEM: 2.91 +/- 1.05 mumol/g wet tissue bone) and two had high plasma ferritin. Haemodialysis and haemofiltration were performed using a highly permeable membrane. The adequate dose of desferrioxamine for aluminium removal is 40mg/kg, since aluminium mass transfer induced by haemodialysis and haemofiltration (47.4 and 40 mumol/session) are not significantly different from that obtained with 80mg/kg. Iron removal is dose related in high plasma ferritin concentration patients: 50 and 100 mumol/session with haemodialysis and 29 and 175 mumol/session with haemofiltration after 40 and 80mg/kg body weight respectively.
Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985
PMID:Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion. 399 42

In order to develop an experimental IgA nephropathy, C3H/HeJ mice, high producers of IgA, were strongly immunised orally by ferritin and compared to C3H/eB mice. After immunisation, serum IgA and IgG titres increased significantly only in C3H/HeJ mice. Specific antiferritin antibody could be detected in the serum. Mesangial IgA deposits were present in most of C3H/HeJ mice after immunisation and were significantly higher than in C3H/eB mice. No ferritin deposits could be detected in the kidney. No clinical manifestation appeared in these animals.
Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985
PMID:IgA mesangial deposits in C3H/HeJ mice after oral immunisation. 399 63

Forty-eight haemodialysis patients were divided in two groups according to presence or absence of haemochromatosis alleles (HA). Serum ferritin concentrations were determined and analysed according to blood transfusion history. Furthermore 20 patients were given iron saccarate and post treatment ferritin concentrations were determined at 15 and 30 days. Following blood transfusion, only HA+ patients increased ferritin concentrations, while intravenous iron administration produced increased ferritin both in HA+ and HA- patients. Therefore it is advisable to minimise transfusions in HA+ patients, while intravenous iron administration should be avoided regardless of HA status.
Proc Eur Dial Transplant Assoc 1983
PMID:Transfused and pharmacological iron: relationship of overload to HLA antigens. 665 49

Elevated serum alanine aminotransferase (ALT) for more than one year was found in 36 (28.8%) of 125 patients on maintenance haemodialysis. In 10 the ALT returned to normal spontaneously but in 26 it remained high. Liver tissue from 21 patients with high ALT and seven with normal ALT was examined. Statistically significant correlations were found between the mean ALT during the year prior to the biopsy and assessments of the lymphocytic infiltration (p less than 0.001), fibrosis (p less than 0.001) and amount of silicone particles in the liver (p less than 0.001). Epithelioid cell granulomata, lobular and portal macrophages and perivenular fibrosis were related to silicone particles. Lymphocytes were not spacially related to the particles; nevertheless, there was a significant correlation between amounts of silicone and lymphocytic infiltration (p less than 0.01). No associations were found between high ALT, hepatitis B serology, serum ferritin, parenchymal siderosis, propensity to fluid overload, alcohol abuse and HLA-B8.
Proc Eur Dial Transplant Assoc 1983
PMID:Chronic liver disease in haemodialysis patients. 687 29

Twelve patients being treated by intermittent haemodialysis developed a severe microcytic hypochromic anaemia despite adequate iron supplements. Serum ferritin concentration was normal or high. Seven patients later developed histologically proven fracturing osteomalacia and one a fatal encephalopathy. Plasma aluminium concentration was high in all twelve patients and the source was the water used to make up dialysis fluid. Following dialysis with aluminium free dialysis fluid, plasma concentrations of aluminium fell, red cell morphology returned to normal and haemoglobin rose. We believe that in addition to causing encephalopathy and osteomalacia, aluminium causes a microcytic hypochromic anaemia. This anaemia appears to be the first manifestation of aluminium intoxication and is reversed by removing the source of aluminium.
Proc Eur Dial Transplant Assoc 1980
PMID:Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. 724 73

Recombinant human erythropoietin (r-HuEPO) therapy is expensive, and it is therefore important to optimize its use to satisfy the health economist as well as the prescriber. Five main issues can be considered in helping to achieve this goal: (i) Route and site of administration. Much evidence suggests that subcutaneous (s.c.) administration of r-HuEPO is more cost-effective than intravenous (i.v.) administration, i.e. lower s.c. doses may be used to achieve the same effect. There are, however, some studies which suggest that there is little to choose between the two routes. One pharmacokinetic study in normal volunteers found that s.c. injection of r-HuEPO into the thigh resulted in greater peak values and greater bioavailability than s.c. injection into the arm or abdomen. (ii) Frequency of injection. There are now reports of dialysis patients being variously treated with once-weekly, twice-weekly, thrice-weekly, and once-daily s.c. administration of r-HuEPO. Despite some comparative studies, the optimum dosing frequency for s.c. r-HuEPO remains unclear. (iii) Iron status. Failure of an adequate supply of iron to the erythron is probably the most common and most easily treated cause of sub-optimal response to r-HuEPO. Effective and regular monitoring of iron status by measurement of serum ferritin, transferrin saturation, and per cent hypochromic red cells is critical to the management of the patient receiving r-HuEPO, and there is increasing evidence that liberal use of i.v. iron may enhance the response to this treatment. (iv) Other factors affecting response to r-HuEPO.(ABSTRACT TRUNCATED AT 250 WORDS)
Nephrol Dial Transplant 1995
PMID:How to get the best out of r-HuEPO. 764 12

Inadequate iron supply is probably the most common and most easily treated cause of sub-optimal response to recombinant human erythropoietin (r-HuEPO). A low ferritin value is a reliable indicator of iron deficiency, provided that patients are in equilibrium (e.g. without infection, bleeding, vitamin or folate deficiency). Normal or high ferritin values do not necessarily preclude iron deficiency. Transferrin saturation is not always a reliable indicator of iron deficiency. The measure which best reflects iron supply to the erythron is the percentage of hypochromic red cells. Iron supplementation should be targeted at keeping serum ferritin > 100 micrograms/l, transferrin saturation > 20%, and hypochromic red cells < 10%. Iron status should be monitored monthly for the first few months after initiation of r-HuEPO, and thereafter at 2-3 month intervals. For haemodialysis patients, who have a very high rate of iron loss, i.v. iron administration is preferable and may also be appropriate for patients on continuous ambulatory haemodialysis (CAPD) and pre-dialysis patients. Recent studies with i.v. iron supplementation have shown no difference between the s.c. and i.v. routes of administration of r-HuEPO. Both the i.v. and the s.c. route are appropriate for patients on haemodialysis, whereas patients on CAPD or pre-dialysis patients should receive s.c. r-HuEPO. The optimum frequency of s.c. administration in the vast majority of patients is 2-3 times weekly. For a small number of patients, once weekly s.c. administration may be suitable. When satisfactory haemoglobin values are reached, the dose of r-HuEPO should be titrated down gradually. It should not be stopped abruptly unless there are life-threatening complications.
Nephrol Dial Transplant 1995
PMID:How to get the best out of r-HuEPO. 764 13

All adult patients from 13 dialysis centres were prospectively followed up for 6 months in an attempt to appraise the current risk factors for bacterial infections in stable chronically haemodialysed patients. Parameters recorded as potential risk factors for BI were age, gender, cause of renal failure, time elapsed since the start of dialysis, history of transplantation, recent surgical procedure, previous bacterial infection, current immunosuppressive or erythropoietin therapy, type of angioaccess device, and serum ferritin level. Six hundred and seven patients (mean age 56.5 years, range 18-85) were enrolled in the study. Mean time elapsed since the start of dialysis was 4.7 years. One hundred and eighteen patients had developed at least one bacterial infection during the study period whereas 489 had remained free of bacterial infection at the end of the follow-up. In multivariate analysis three parameters were found to be significant and independent risk factors for bacterial infection: previous history of bacterial infection (at least one versus no previous episode), type of angioaccess device (catheter versus native fistula), and elevated serum ferritin level (greater versus lower than 500 micrograms/l). These results support the evidence that impaired host defences in chronic haemodialysis patients may be secondary to the dialysis procedure and suggest that the incidence of bacterial infection in these patients may be further reduced by appropriate supportive therapy.
Nephrol Dial Transplant 1995
PMID:Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. 779 34

Ten continuous ambulatory peritoneal dialysis (CAPD) patients experienced 23 episodes of peritonitis and were treated with intraperitoneal (IP) antibiotics as per sensitivity report. Serum ferritin was measured before and after the treatment. In 6 patients, erythropoietin (EPO) was also measured before and after the treatment. There was a significant drop in the serum EPO levels after therapy compared to the levels before, whereas serum ferritin levels did not change.
Adv Perit Dial 1994
PMID:Increased need of erythropoietin during peritonitis in children on continuous peritoneal dialysis. 799 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>